International Clinical Trial: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics profile of a single subcutaneous administration of YKYY032 Injection in Healthy participants with elevated Lipoprotein(a)

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600116025) titled 'A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics profile of a single subcutaneous administration of YKYY032 Injection in Healthy participants with elevated Lipoprotein(a)' on Jan. 4.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Peking University First Hospital

Condition: Hyperlipoproteinemia(a)

Intervention: YKYY032 injection group:Dosage Form: Injection Strength: 0.5ml : 100mg (calculated as YKYY032) Dosage and Administration: Participants shall be assigned to corresponding ...